O‘zbekiston кardiologiyasi 2-tom 1-san (2025) · 4-10-betler
Comparison of the effectiveness of the original and generic forms of clopidogrel in patients with coronary artery disease (CAD).4o
Муллабаева, Г, Хайруллаев, У, Mullabaeva, Guzal, Xairullaev, Umid, Mullabaeva, Guzal, Khairullaev, Umid
Annotaciya
Background. To evaluate the antiaggregation activity and clinical tolerability of Areplex (75 mg, ADAMED, Poland) compared to Plavix (75 mg, Sanofi-Winthrop Industrie, France) in CAD patients. Materials and methods. A blinded, randomized, two-parallel-group study included 40 patients with stable angina (FC I-IV). Platelet aggregation was assessed using the AP 2110 analyzer (SOLAR) with ADP (5 µmol/L) and arachidonic acid (0.5 mg/mL) inducers after a 300 mg loading dose. Results. At 24 hours post-dose, both groups showed significant reductions in aggregation degree and rate (p<0.05), with no intergroup differences (p>0.05). Safety profiles were comparable, with no adverse events reported. Conclusion. Areplex demonstrated bioequivalence to Plavix, with good tolerability, supporting its use as an effective antiplatelet agent in CAD patients.
bioequivalenceclopidogrelareplexplavixcoronary artery diseaseantiplatelet therapyбиоэквивалентностьклопидогрельареплексплавикс
Metadata derekkózi: jurnal OAI-PMH arxivi · Sindex tolıq mátindi saqlamaydı, derekkózge silteme beredi.